Table 1.
Patient characteristics
| Variables | Total |
PTCY |
ATG |
P value |
|---|---|---|---|---|
| N (%) | n (%) | n (%) | ||
| Patient number | 960 (100) | 209 (21.8) | 751 (78.2) | |
| Median age at transplant (IQR), y | 59.3 (49.2-65) | 57.1 (46.5-63.9) | 60.1 (50.6-65.2) | .006 |
| Sex at birth | ||||
| Male | 603 (62.8) | 122 (58.4) | 481 (64.0) | .16 |
| Female | 357 (37.2) | 87 (41.6) | 270 (36.0) | |
| Patient CMV serology | ||||
| Positive | 673 (71.1) | 160 (77.7) | 513 (69.2) | .023 |
| Negative | 274 (28.9) | 46 (22.3) | 228 (30.8) | |
| Missing | 13 | 3 | 10 | |
| Disease at diagnosis | ||||
| RA/RARS/del5q | 69 (7.4) | 16 (7.7) | 53 (7.3) | .54 |
| RCMD/RCMD-RS/MDS-U | 292 (31.2) | 58 (28.0) | 234 (32.1) | |
| MDS-EB | 576 (61.5) | 133 (64.3) | 443 (60.7) | |
| Missing | 23 | 2 | 21 | |
| IPSS-R at diagnosis | ||||
| Very low | 35 (6.6) | 6 (4.4) | 29 (7.3) | .24 |
| Low | 86 (16.1) | 16 (11.8) | 70 (17.6) | |
| Intermediate | 146 (27.4) | 36 (26.5) | 110 (27.7) | |
| High | 157 (29.5) | 46 (33.8) | 111 (28.0) | |
| Very high | 109 (20.5) | 32 (23.5) | 77 (19.4) | |
| Missing | 427 | 73 | 354 | |
| Cytogenetics | ||||
| Normal | 396 (45.6) | 86 (46.0) | 310 (45.5) | .98 |
| Abnormal | 472 (54.4) | 101 (54.0) | 371 (54.5) | |
| Missing | 92 | 22 | 70 | |
| IPSS-R cytogenetics | ||||
| Good | 448 (53.6) | 99 (55.0) | 349 (53.2) | .95 |
| Intermediate | 141 (16.9) | 28 (15.6) | 113 (17.2) | |
| Poor | 124 (14.8) | 27 (15.0) | 97 (14.8) | |
| Very poor | 123 (14.7) | 26 (14.4) | 97 (14.8) | |
| Missing | 124 | 29 | 95 | |
| Treatment before HSCT | ||||
| Untreated | 232 (24.4) | 47 (22.6) | 185 (24.9) | .55 |
| Treated | 718 (75.6) | 161 (77.4) | 557 (75.1) | |
| Missing | 10 | 1 | 9 | |
| HMA before HSCT | ||||
| Yes | 411 (45.3) | 111 (56.1) | 300 (42.3) | .001 |
| No | 496 (54.7) | 87 (43.9) | 409 (57.7) | |
| Missing | 53 | 11 | 42 | |
| Disease at HSCT | ||||
| MDS without EB | 232 (24.7) | 50 (24.3) | 182 (24.8) | .56 |
| MDS with EB | 503 (53.5) | 116 (56.3) | 387 (52.7) | |
| MDS-AML | 206 (21.9) | 40 (19.4) | 166 (22.6) | |
| Missing | 19 | 3 | 16 | |
| Donor type | ||||
| MUD (10/10) | 672 (70) | 112 (53.6) | 560 (74.6) | <.001 |
| MMUD | 288 (30) | 97 (46.4) | 191 (25.4) | |
| 9/10 | 241 (83.7) | 79 (81.4) | 162 (84.8) | .72 |
| 8/10 | 45 (15.6) | 17 (17.5) | 28 (14.7) | |
| 7/10 | 2 (0.7) | 1 (1.0) | 1 (0.5) | |
| Performance status | ||||
| >80 | 661 (71.3) | 150 (72.8) | 511 (70.9) | .65 |
| ≤80 | 266 (28.7) | 56 (27.2) | 210 (29.1) | |
| Missing | 33 | 3 | 30 | |
| HCT-CI | ||||
| Low | 422 (45.7) | 89 (43.4) | 333 (46.4) | .31 |
| Intermediate | 234 (25.4) | 48 (23.4) | 186 (25.9) | |
| High | 267 (28.9) | 68 (33.2) | 199 (27.7) | |
| Missing | 37 | 4 | 33 | |
| Conditioning regimen | ||||
| MAC | 408 (42.5) | 116 (55.8) | 292 (38.9) | <.001 |
| RIC | 551 (57.5) | 92 (44.2) | 459 (61.1) | |
| Missing | 1 | 1 | ||
| Stem cell source | ||||
| BM | 59 (6.1) | 12 (5.7) | 47 (6.3) | .91 |
| PB | 901 (93.9) | 197 (94.3) | 704 (93.7) | |
| GVHD prophylaxis | ||||
| Calcineurin inhibitors | 905 (94.3) | 169 (80.9) | 736 (98.0) | <.001 |
| MMF | 434 (45.2) | 124 (59.3) | 310 (41.3) | <.001 |
| Methotrexate | 402 (41.9) | 3 (1.4) | 399 (53.1) | <.001 |
BM, bone marrow; CMV, cytomegalovirus; MDS-AML, myelodysplastic syndrome transformed to AML; MDS-U, myelodysplastic syndrome unclassifiable; PB, peripheral blood; R, refractory anemia; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and with ring sideroblasts.